Ubrogepant Eases Acute Migraine Pain, New Data Confirm Ubrogepant Eases Acute Migraine Pain, New Data Confirm

Final results from the ACHIEVE II randomized, placebo-controlled trial confirm the safety and efficacy of the CGRP antagonist for acute migraine. FDA action is expected next month.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Neurology & Neurosurgery News Source Type: news